Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27896885 | 0.94 | MAPT (0.52) | MAPTALDH1A1KDM4EGAAPTK2B | |
| SCHEMBL16583186 | 0.81 | TRIM24 (0.52) | MAPTALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL151261 | 0.80 | CHEK1 (0.68) | MAPTALDH1A1KDM4EGAAPTK2B | |
| SCHEMBL7496780 | 0.80 | KDM4E (0.57) | MAPTALDH1A1KDM4EGAAPTK2B | |
| SCHEMBL13353048 | 0.80 | MAPT (0.57) | MAPTALDH1A1KDM4EGAAPTK2B | |
| SCHEMBL6405205 | 0.79 | GAA (0.61) | MAPTKDM4EGAAADRA2CGFER | |
| SCHEMBL4871815 | 0.79 | ALDH1A1 (0.53) | MAPTALDH1A1KDM4EGAAGFER | |
| SCHEMBL517732 | 0.78 | LMNA (0.52) | MAPTALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL11025720 | 0.77 | GAA (0.63) | MAPTALDH1A1KDM4EGAAPTK2B | |
| SCHEMBL6223030 | 0.77 | CHKA (0.51) | MAPTALDH1A1KDM4EGAAPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102174035-B | Aromatic dihydrazide type PLK1 (Polo-like Kinase 1) inhibitor and applications thereof | UNIV CHINA PHARMA | 2015-01-07 | — | — | CN | claimed |
| CN-103102314-A | Benzothiazole, benzimidazole, benzoxazole derivatives and preparation method and application thereof | UNIV SICHUAN | 2013-05-15 | — | — | CN | claimed |
| CN-102174035-A | Aromatic dihydrazide type PLK1 (Polo-like Kinase 1) inhibitor and applications thereof | UNIV CHINA PHARMA | 2011-09-07 | — | — | CN | claimed |
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | claimed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | claimed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-103201267-B | AMPK-activating heterocyclic compounds and methods of use thereof | 里格尔药品股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2016-08-11 | — | — | US | disclosed |
| US-9266856-B2 | AMPK—activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| CN-102174035-A | Aromatic dihydrazide type PLK1 (Polo-like Kinase 1) inhibitor and applications thereof | UNIV CHINA PHARMA | 2011-09-07 | — | — | CN | disclosed |
| CN-101611014-A | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2051985-A2 | PYRAZOLO[4,3-D]THIAZOLE DERIVATIVES, AND PREPARATION AND THERAPUETIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008015340-A2 | PYRAZOLO[4,3-D]THIAZOLE DERIVATIVES, AND PREPARATION AND THERAPUETIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-02-07 | — | — | WO | disclosed |
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | MAPT 2435/4885ALDH1A1 807/4885KDM4E 926/4885 |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | AK2, PC, PRKAG2 | MAPT 2071/4885ALDH1A1 1146/4885KDM4E 752/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | MAPT 2435/4885ALDH1A1 807/4885KDM4E 926/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | MAPT 2435/4885ALDH1A1 807/4885KDM4E 926/4885 |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | MAPT 2884/4885ALDH1A1 2068/4885KDM4E 3579/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | MAPT 2435/4885ALDH1A1 807/4885KDM4E 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.